Compare ACB & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACB | CRBU |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 203.9M |
| IPO Year | 2016 | 2021 |
| Metric | ACB | CRBU |
|---|---|---|
| Price | $3.44 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 558.5K | ★ 1.2M |
| Earning Date | 02-04-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.89 | N/A |
| Revenue Next Year | N/A | $10.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.28 | $0.66 |
| 52 Week High | $6.67 | $3.53 |
| Indicator | ACB | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 54.05 |
| Support Level | $3.28 | $1.70 |
| Resistance Level | $3.91 | $2.07 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 7.11 | 60.98 |
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.